Dr Cascalló is the Chief Executive Officer and Chairman of the Board of Directors of VCN Biosciences and one of its founders. Dr Cascalló is an expert in oncolytic therapies and gene therapy and author of many original scientific papers and reviews in peer-reviewed journals, as well as co-inventor of 6 patents on the use of adenovirus as antitumoral agents. He has been involved in the clinical development of different oncolytic adenoviruses as researcher at the University of Barcelona (Spain), the MD. Anderson Cancer Center (USA), Merck (Spain), and the Virotherapy Group at Institut Català d'Oncologia (ICO/IDIBELL)(Spain). Dr. Cascalló has also acted as Expert for the European Medicines Agencies (EMA) and has received management formation at Cambridge University (UK) and IESE Business School (Spain).